High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients with High-risk Stage 3 Neuroblastoma: 10-Year Experience at a Single Center by Suh, Jung Min et al.
High-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was
applied to improve the prognosis of patients with high-risk stage 3 neuroblastoma.
From January 1997 to December 2006, 28 patients were newly diagnosed as stage
3 neuroblastoma. Nine of 11 patients with N-myc amplification and 5 of 17 patients
without N-myc amplification (poor response in 2 patients, persistent residual tumor
in 2 and relapse in 1) underwent single or tandem HDCT/ASCR. Patients without
high-risk features received conventional treatment modalities only. While 8 of 9
patients underwent single HDCT/ASCR and the remaining one patient underwent
tandem HDCT/ASCR during the early study period, all 5 patients underwent tan-
dem HDCT/ASCR during the late period. Toxicities associated with HDCT/ASCR
were tolerable and there was no treatment-related mortality. While the tumor relapsed
in two of eight patients in single HDCT/ASCR group, all six patients in tandem HDCT/
ASCR group remained relapse free. The 5-yr event-free survival (EFS) from diag-
nosis, in patients with N-myc amplification, was 71.6±14.0%. In addition, 12 of 14
patients who underwent HDCT/ASCR remained event free resulting in an 85.1±
9.7% 5-yr EFS after the first HDCT/ASCR. The present study demonstrates that
HDCT/ASCR may improve the survival of patients with high-risk stage 3 neuro-
blastoma. 
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INTRODUCTION
The prognosis of stage 3 neuroblastoma is generally good
(1, 2). However, the prognosis of stage 3 neuroblastoma with
unfavorable biologic factors, such as, N-myc amplification, is
poor with conventional chemoradiotherapy (1, 3). In addition,
the prognosis of stage 3 neuroblastoma with a poor response
to conventional treatment (4-6) or with relapse during con-
ventional treatment is also poor even when the tumor did
not have unfavorable biologic factors. 
A strategy using high-dose chemotherapy and autologous
stem cell rescue (HDCT/ASCR) has been explored to improve
the prognosis of patients with high-risk neuroblastoma (7-
11). This strategy is based on the hypothesis that a dose esca-
lation might improve the survival of children with high-risk
neuroblastoma. The results of randomized trials, comparing
HDCT/ASCR with chemotherapy alone, showed a better
event-free survival (EFS) in the HDCT/ASCR arm than in
the continuous chemotherapy arm (8, 11). Recently, inves-
tigators have examined the efficacy of double or triple tan-
dem HDCT/ASCR to further improve the outcome of high-
risk neuroblastoma patients. Sung et al. (12) and George et
al. (13) carried out a single arm trial of tandem transplanta-
tion as consolidation therapy, and reported improved long-
term survival (5-yr progression-free survival 62% and 47%,
respectively) with acceptable toxicity. Kletzel et al. also con-
ducted a single arm trial of triple tandem transplantation and
reported improved survival (3-yr EFS 57%) (14). They demon-
strated that further dose escalation using sequential HDCT/
ASCR might result in further improvements in the survival
of patients with high-risk neuroblastoma. 
However, a majority of patients in their studies had stage
4 tumors and only a small proportion of patients had stage 3
high-risk tumors. Therefore, the efficacy of HDCT/ASCR for
stage 3 high-risk patients was not shown in their reports (7-
14). The number of studies evaluating the efficacy of HDCT/
ASCR only in patients with high-risk stage 3 neuroblastoma
is limited. In this context, the present study examined the
efficacy of HDCT/ASCR in order to determine if a dose inten-
sification strategy might improve the EFS in patients with
high-risk stage 3 neuroblastoma. 
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MATERIALS AND METHODS
Patients
From January 1997 to December 2006, 28 consecutive
patients were newly diagnosed as stage 3 neuroblastoma at
the Samsung Medical Center. A diagnosis of neuroblastoma
was made based on either histological examination of the
tumor specimens or bone marrow infiltrated with neurob-
lastoma cells and elevated urine catecholamine levels. The
N-myc copy number was determined using Southern blot
analysis or quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR). The patients were staged according to
the criteria reported by Brodeur et al. (15) and the extent of
the disease was evaluated using computerized tomography,
a technetium-99 (99Tc) bone scan, bilateral bone marrow aspi-
rates and biopsy specimens, and an iodine-131 or 123-me-
taiodobenzylguanidine scan. Measurement of serum lactate
dehydrogenase, ferritin and neuron-specific enolase was part
of the routine evaluation at diagnosis.
Treatment of patients
Fig. 1 summarizes the treatment. Most patients received
5-6 cycles of chemotherapy before definitive surgery, except
for those patients that had a surgical resection before the ad-
ministration of chemotherapy. If it was difficult to debulk
the tumor, an additional 1-2 cycles of chemotherapy were
given prior to the definitive surgery. 
For patients with N-myc amplified tumors, patients with
a very poor response to chemotherapy or patients with per-
sistent gross residual tumor after surgery, the peripheral blood
stem cells (PBSCs) were collected during the next chemother-
apy cycle after surgery. After collecting the PBSCs, 0-2 addi-
tional cycles of chemotherapy were given prior to the HDCT/
ASCR. For patients without N-myc amplification who res-
ponded well, continuous chemotherapy was provided after
surgery (total 12 cycles). 
Table 1 lists the chemotherapy regimens used in the pre-
sent study. During the early period of the study (diagnosis
by December 2003), the cisplatin, etoposide, doxorubicin and
cyclophosphosphamide (CEDC) regimen was used as the pri-
mary treatment. In the late period (diagnosis from January
2004), alternating CEDC and ifosfamide, carboplatin and
etoposide (ICE) regimens were used. While all the patients
in the late study period received 9 cycles of chemotherapy
prior to the HDCT/ASCR, 7 of 9 patients in the early study
period received 6 or 7 cycles of chemotherapy. Each chemo-
therapy cycle was scheduled to be 28 days apart but some de-
lays were permitted in order to allow the absolute neutrophil
count (ANC) and platelet count to recover to 1,000/μ L and
100,000/μ L, respectively. The patients received 5-10 μ g/kg
of subcutaneous human granulocyte-colony stimulating fac-
Fig. 1. Flow of the patients from diagnosis through HDCT/ASCR.
All except two patients with N-myc amplification (early death in 1
and refusal to receive HDCT in 1) underwent HDCT/ASCR. In addi-
tion, 5 of 17 patients without N-myc amplification (poor response
to chemotherapy in 2 patients, persistent gross residual tumor in
2 patients and relapse during chemotherapy in 1 patient) under-
went HDCT/ASCR. Therefore, overall 14 patients underwent HDCT/
ASCR. Eleven of 17 patients without N-myc amplification received
conventional chemotherapy alone.
Total patients
(n=28)
Amplified
(n=11)
HDCT/ASCR
(n=9)
Conventional 
chemotherapy (n=1)
Early toxic death
(n=1)
Conventional 
chemotherapy (n=11)
Early toxic death
(n=1)
HDCT/ASCR
poor response (n=2)
gross residual tumor (n=2)
relapse (n=1)
Not amplified
(n=17)
N-myc
HDCT, high-dose chemotherapy.
Regimens Dosage Schedule
Conventional chemotherapy
CEDC
Cisplatin 60 mg/m
2/day Day 0
Etoposide 100 mg/m
2/day Days 2 & 5
Doxorubicin 30 mg/m
2/day Day 2
Cyclophophamide 30 mg/kg/day Days 3 & 4
ICE
Ifosfamide 1,200 mg/m
2/day Days 0-4
Carboplatin 400 mg/m
2/day Days 0 & 1
Etoposide 100 mg/m
2/day Days 0-4
First HDCT regimens
CEM
Carboplatin 300 mg/m
2/day Days -6, -5, -4, -3
Etoposide 200 mg/m
2/day Days -6, -5, -4, -3
Melphalan 140 mg/m
2/day Day -5
70 mg/m
2/day Day -4
CEC
Carboplatin 650 mg/m
2/day Days -7, -6, -5
Etoposide 650 mg/m
2/day Days -7, -6, -5
Cyclophosphamide 1,800 mg/m
2/day Days -4, -3, -2
Second HDCT regimens
CTM
Carboplatin 250 mg/m
2/day Days -6, -5, -4
Thiotepa 200 mg/m
2/day Days -6, -5, -4
Melphalan 160 mg/m
2/day Day -3
TM
Thiotepa 300 mg/m
2/day Days -7, -6, -5
Melphalan 60 mg/m
2/day Days -4 & -3
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tor (G-CSF) daily if the ANC fell below 500/μ L after chemo-
therapy. 
PBSC collection
The patients received 5-10 μ g/kg of subcutaneous G-CSF
daily if the ANC fell below 500/μ L after chemotherapy, and
G-CSF was continued until the completion of leukapheresis.
Leukapheresis was started when the white blood cell count
exceeded 1,000/μ L with a monocytosis after the nadir. The
aim was to collect a minimum of 2×106 CD34+ cells/kg
(hopefully >5×106 cells/kg) in order to rescue the probable
tandem HDCT with the PBSCs collected during a single
leukapheresis round. 
HDCT and ASCR
Table 1 lists the HDCT regimens used in the present study.
While only one patient who was not in complete response
(CR), even after the first HDCT/ASCR, underwent a second
HDCT/ASCR in the early period of this study, all the pati-
ents in the late period underwent tandem HDCT/ASCR. The
HDCT regimens employed for the first HDCT were carbop-
latin, etoposide and melphalan (CEM) in the early period
and CEC in the late period. The regimens employed for the
second HDCT were carboplatin, thiotepa, and melphalan
(CTM) in the early period and TM in the late period. Total
body irradiation (TBI) was not included in the HDCT regi-
men. The second HDCT/ASCR was given only if the platelet
count exceeded 50,000/μ L after the first HDCT/ASCR, with-
out a transfusion, and if there was no evidence of significant
organ dysfunction. Approximately half of the collected PBSCs
were infused for marrow rescue at each HDCT session. Sam-
sung Medical Center Institutional Review Board approved
the protocols used for the HDCT/ASCR, and written informed
consent was obtained from the parents of each patient.
Local radiotherapy
In the early period of this study, local radiotherapy (15 Gy/
1.5 Gy in the case of small residual tumor and 21.6 or 30.6
Gy/1.8 Gy in the case of bulky residual tumor) was given to
the primary site only if gross residual tumor remained after
surgery. However, in the late period, local radiotherapy (15
Gy/1.5 Gy in the case of complete resection of the primary
tumor and 21.6 Gy/1.8 Gy in the case of incomplete resec-
tion) was administered to all patients (4 weeks after the com-
pletion of conventional chemotherapy or 6 weeks after the
second HDCT/ASCR).
Post-HDCT treatment
Thirteen-cis-retinoic acid (CRA) was used for 10 cycles (125
mg/m2/day for 14 days per every 4 weeks) to differentiate the
possible minimal residual tumor cells. Differentiation ther-
apy with CRA was initiated 60-90 days after the HDCT/
ASCR or 30 days after the completion of conventional che-
motherapy. Immunotherapy using interleukin-2 (IL-2) was
administered (2×106 U/m2/day, subcutaneous injection, days
0-4, every 4 weeks) with or without preceding induction ther-
apy (3×106 U/m2/day, continuous infusion, days 0-4 and 7-
11) (16). IL-2 immunotherapy was initiated when the platelet
count exceeded 50,000/μ L, without a transfusion, after the
HDCT/ASCR. The first dose of IL-2 was provided on the
first day of the CRA treatment cycle and was continued until
1 yr after the HDCT/ASCR. Immunotherapy was not used
in patients who received conventional chemotherapy alone.
Response criteria
The international response criteria were used to evaluate
the treatment response (15). Briefly, a CR was defined as no
identifiable tumor with normal catecholamine levels. A very
good partial response (VGPR) was defined as a decrease in
the primary tumor by 90-99% with normal catecholamine
levels with or without any residual 99Tc bone changes. A par-
tial response (PR) was defined as a reduction of the primary
tumor and metastatic tumor by more than 50%. The toxic-
ity was recorded according to the common toxicity criteria
of the National Cancer Institute of the U.S.A.
Statistics
The survival rate along with the standard error (SE) was
estimated using the Kaplan-Meier method. An event was
defined as the occurrence of a relapse, progression or treat-
ment-related death. The differences in the survival rates bet-
ween the two groups (single HDCT versus tandem HDCT,
N-myc amplified versus not amplified) were compared using
the log-rank test. The differences in the ANC and platelet
recovery between the first and second HDCT/ASCR were
analyzed using a paired t-test. P values <0.05 were consid-
ered significant.
RESULTS
Patient characteristics 
Table 2 lists the clinical and biological characteristics of all
28 patients. The median age of the 28 patients (15 males and
13 females) at diagnosis was 23.5 months (range 1-95), and
19 patients (67.9%) were over 12 months of age at diagno-
sis. Eleven out of 28 tumors (39.3%) were N-myc amplified
(≥3 copies) and 10 (35.7%) had unfavorable Shimada pathol-
ogy. The primary site of the tumors was the abdomen in 23
patients, mediastinum in 4 patients and neck in 1 patient.High-dose Chemotherapy in High-risk Stage 3 Neuroblastoma 663
Treatment prior to HDCT/ASCR
Fig. 1 shows the flow of patients from diagnosis through
HDCT/ASCR. All except two patients with N-myc amplifi-
cation (early death in 1 and refusal to receive HDCT in 1)
underwent HDCT/ASCR. In addition, five of 17 patients
without N-myc amplification (poor response to chemothera-
py in 2 patients, persistent gross residual tumor in 2 patients
and relapse during chemotherapy in 1 patient) underwent
HDCT/ASCR. Therefore, overall, 14 patients underwent
HDCT/ASCR. Eleven of 17 patients without N-myc ampli-
fication received conventional chemotherapy alone. 
Table 3 lists the clinical and biological characteristics of
14 patients who underwent HDCT/ASCR. Overall, a medi-
an of 8 cycles (range 6-14) of chemotherapy was administered
before the first HDCT/ASCR. Five out of 14 patients received
local radiotherapy after surgery. The tumor status prior to the
first HDCT was CR in 7, VGPR in 5 and PR in 2. 
Feasibility of PBSC collection
The PBSCs were collected during the sixth to eighth che-
motherapy cycle. A median of 6.5×106CD34+cells/kg (range
2.1-17.9) were collected during a median of four leukaphere-
sis events (range 2-11). Generally, the leukapheresis procedure
was well tolerated and no patient developed significant tox-
icity except for thrombocytopenia requiring a transfusion after
leukapheresis in all patients. During the late period of this
study, quantitative RT-PCR for tyrosine hydroxylase mRNA
was performed to detect possible tumor cell contamination
in the PBSCs collected from five patients, and no mRNA
transcript was detected (12). 
HDCT/ASCR
Fourteen out of 28 patients underwent at least one HDCT/
ASCR. The median age at the first HDCT/ASCR was 30.5
months (range 16-70). The tumor status after the first HDCT/
ASCR was CR in 12 and VGPR in 2. One out of nine patients
in the early period and all five in the late period underwent
a second HDCT/ASCR. The median time from the first infu-
sion of PBSCs to the initiation of the second HDCT was 82.5
days (range 66-88).  *Median (range).
Number (%) (n=28) Parameters
Sex
Female 13 (46.4)
Male 15 (53.6)
Age
<12 months 9 (32.1)
≥12 months 19 (67.9)
N-myc gene
Amplified (≥3 copies) 11 (39.3)
Not amplified (<3 copies) 17 (60.7)
Pathology (Shimada classification)
Favorable 17 (60.7)
Unfavorable 10 (35.7)
Undetermined 1 (3.6)
Primary site
Abdomen 23 (82.1)
Others 5 (17.9)
Lactate dehydrogenase (IU/L) 1,002 (367-6,744)*
Ferritin (ng/mL) 76 (10-1,129)
Neuron-specific enolase (ng/mL) 45 (8-529)
Vanyl-mandellic acid (mg/day) 5.3 (0.2-54.1)
Table 2. Clinical and biological characteristics at diagnosis
Age
at Dx
(mon)
N-myc
Pathology
(Shimada)
Primary
site
Reason 
for HDCT
Tumor 
status
at HDCT1
Outcome
FU from
HDCT1
(mon)
RT
timing
HDCT2
regi-
men
HDCT1
regi-
men
Pre-HDCT
chemotherapy
UPN
5 27 A UF Abdomen CEDC×6 High-risk CR CEM - ND 110 + Ds free
7 7 NA F Abdomen CDEC×9 Persistent PR CEM CTM After surgery  94 + Ds free
and HDCT2
8 31 A UF Abdomen CEDC×6 High-risk CR CEM - ND 15 Relapse
10 15 A F Abdomen CEDC×6 High-risk VGPR CEM - After surgery 83 + Ds free
11 33 A UF Abdomen CEDC×6 High-risk CR CEM - ND 79 + Ds free
12 63 A UF Abdomen CEDC×6 High-risk VGPR CEM - After surgery 7 Relapse
14 10 NA F Abdomen CEDC×13, ICE×1 Relapse CR CEM - After relapse 58 + Ds free
17 17 A UF Abdomen CEDC×6 High-risk VGPR CEM - After surgery 57 + Ds free
18 25 A F Chest CEDC×3, ICE×4 High-risk VGPR CEM - After surgery 53 + Ds free
21 7 A F Abdomen CEDC×5, ICE×4 High-risk VGPR CEC TM After HDCT2 19 + Ds free
22 13 NA F Chest CEDC×5, ICE×4 Poor response CR CEC TM After HDCT2 18 + Ds free
23 32 NA F Abdomen CEDC×5, ICE×4 Poor response CR CEC TM After HDCT2 16 + Ds free
24 38 NA UF Abdomen CEDC×5, ICE×4 Persistent PR CEC TM After HDCT2 15 + Ds free
25 19 A Unknown Abdomen CEDC×5, ICE×4 High-risk CR CEC TM After HDCT2 12 + Ds free
Table 3. Characteristics of patients who underwent HDCT/ASCR
UPN, unique patient number; Dx, diagnosis; HDCT, high-dose chemotherapy; HDCT1, first HDCT; HDCT2, second HDCT; RT, radiotherapy; FU, fol-
low-up; A, amplified; NA, not amplified; F, favorable; UF, unfavorable; ND, not done; ds, disease; mo, months.664 J.M. Suh, K.H. Yoo, K.W. Sung, et al.
A median of 4.0×106 CD34+ cells/kg (range 0.6-13.0)
were infused for the first HDCT/ASCR, and the median time
required to reach an ANC of 500/μ L and a platelet count of
20,000/μ L, without transfusion for the previous 7 days, was
10 days (range 8-14) and 24 days (range 16-38), respectively.
A median of 4.1×106 CD34+ cells/kg (range 1.5-7.3) were
infused for the second HDCT/ASCR and the median time
required to reach an ANC of 500/μ L and a platelet count of
20,000/μ L was 10 days (range 8-14) and 19.5 days (range 14-
220), respectively. When the analysis was confined to only
those patients who had received tandem transplantation, there
were no significant differences in the ANC and platelet recov-
ery between the first and second HDCT/ASCR. 
Table 4 lists the grade 3 and 4 toxicities that developed
during the first and second HDCT/ASCR. The median dura-
tion of high fever (body temperature ≥38.0℃) during the
first and second HDCT/ASCR was 5 and 6.5 days, respec-
tively. There were three microbiologically documented infec-
tions (2 in the first and 1 in the second HDCT/ASCR). The
grade 3 and 4 toxicities that frequently developed in more
than 1/3 of patients were vomiting, elevation of liver enzymes
and hypokalemia. There was no toxic death during the first
and second HDCT/ASCR. No secondary malignancy devel-
oped in this study.
Feasibility of post-HDCT/ASCR therapy
Skin eruption, particularly on the face, was a common side
effect of the CRA treatment. High fever, thrombocytopenia
and local inflammation were frequent side effects of the IL-
2 therapy. However, all patients tolerated the differentiation
therapy and immunotherapy well and there was no grade 3
or 4 toxicity that required the discontinuation of treatment
during the post-HDCT/ASCR therapy.
Survival of patients
The tumor relapsed in three out of all 28 patients and there
were two toxic deaths during the conventional chemothera-
py. Therefore, 23 out of 28 patients remained event free with
a median follow-up of 63 months (range 12-129) from diag-
nosis. The 5-yr EFS rate (±SE) after diagnosis for all 28 pa-
tients was 80.8±7.8% (Fig. 2A). The 5-yr EFS rate, for all
11 patients with N-myc amplification and the 17 patients
without, was 71.6±14.0% and 87.8±8.1%, respectively
(Fig. 2B). 
The tumor relapsed in 2 out of 14 patients who underwent
HDCT/ASCR and the remaining 12 patients remained event
free with a median follow-up of 55 months (range 12-110)
from the first HDCT/ASCR. The 5-yr EFS rate after the first
HDCT/ASCR for all 14 patients who underwent single or
tandem HDCT/ASCR, was 85.1±9.7% (Fig. 3A). While
the tumor relapsed in two of eight patients who underwent
single HDCT/ASCR, all six patients who underwent the tan-
dem HDCT/ASCR remained event free (Fig. 3B). 
First HDCT
(n=14)
Toxicities
Second HDCT
(n=6)
Days of BT ≥38.0°C 5 (2-11)* 6.5 (4-8)*
Documented infection 2 (14.3%) 1 (16.7%)
Stomatitis 2 (14.3%) 3 (50.0%)
Vomiting 4 (28.6%) 2 (33.3%)
Frequency of diarrhea ≥10/day 7 (50.0%) 6 (100%)
Elevation of liver enzyme 14 (100%) 4 (66.7%)
Azotemia 0 (0%) 0 (0%)
Metabolic acidosis 0 (0%) 0 (0%)
Hyponatremia 3 (21.4%) 0 (0%)
Hypokalemia 12 (85.7%) 3 (50.0%)
Hepatic veno-occlusive disease 1 (7.1%) 0 (0%)
Treatment-related mortality 0 (0%) 0 (0%)
Table 4. Grade 3, 4 toxicities during HDCT/ASCR
*Median (range).
BT, body temperature.
Fig. 2. Results of Kaplan-Meier analysis for the EFS in all 28 patients. The tumor relapsed in 3 out of 28 patients and there were 2 toxic deaths
during conventional chemotherapy. Therefore, 23 out of 28 patients remained event free with a median follow-up of 63 months (range 12-
129) from diagnosis. (A) The 5-yr EFS rate (±SE) after diagnosis for all 28 patients was 80.8±7.8%. (B) The 5-yr EFS rate for all 11 patients
with N-myc amplification and 17 patients without was 71.6±14.0% and 87.8±8.1%, respectively. 
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DISCUSSION
Although the prognosis of stage 3 neuroblastoma is gen-
erally good (1, 2), the prognosis of stage 3 neuroblastoma
with unfavorable biologic factors, especially N-myc amplifi-
cation, is poor with conventional chemoradiotherapy (1, 3).
In addition, the prognosis of stage 3 neuroblastoma with a
poor response to conventional treatment (4-6) or with a relapse
during conventional treatment is also poor even when the
tumor did not have unfavorable biologic factors. In this con-
text, HDCT/ASCR was given to patients with high-risk stage
3 neuroblastoma in the present study. As a result, the 5-yr
EFS from diagnosis, in patients with N-myc amplified tumor,
was 71.6±14.0%. In addition, 12 out of 14 patients who
underwent HDCT/ASCR remained event free resulting in
an 85.1±9.7% 5-yr EFS after the first HDCT/ASCR. Sur-
vival rate in the present study is higher than those reported
in the previous trials in which conventional chemotherapy
was given for the treatment of high-risk stage 3 neuroblas-
toma (1, 3). These findings suggest that HDCT/ASCR might
improve the survival of patients with high-risk stage 3 neu-
roblastoma.
Generally, the prognosis of stage 3 neuroblastoma with-
out N-myc amplification is good with conventional chemother-
apy alone (1, 2). However, even in these patients, the prog-
nosis is poor, if the tumor response to conventional chemother-
apy is poor (4) or gross residual tumor remained after surgery
(5, 6). In this context, HDCT/ASCR was given to two pati-
ents with a poor response to conventional chemotherapy and
two patients with a gross residual mass after surgery as well
as patients with N-myc amplified tumor. These four patients
remained event free; the 5-yr EFS for patients without N-myc
amplification was 87.8±8.1% in the present study. In the
present study, HDCT/ASCR contributed to the excellent sur-
vival rate in patients without N-myc amplification in whom
the tumor response to conventional chemotherapy was poor.
In our recent report, on patients over 1 yr of age with stage
4 neuroblastoma, the EFS in patients who received TBI was
better than for patients who did not receive TBI (12). This
suggested that a regimen with TBI was better than a regi-
men without, for the survival of patients, over 1 yr of age,
with stage 4 neuroblastoma. However, TBI was not includ-
ed in the HDCT regimen for high-risk stage 3 patients in
the present study. Although the tumor relapsed in 2 of 14
patients who underwent HDCT/ASCR, the remaining 12
high-risk patients remained event free without TBI. TBI may
increase the frequency and severity of short-term side effects
as well as long-term side effects such as a secondary malig-
nancy several years after treatment (17, 18). The fact that there
was no toxicity-related death during the HDCT/ASCR, in
the present study, might be attributed to the absence of TBI
in our HDCT regimen. Taken together, these findings sug-
gest that our regimen without TBI might be safe and effec-
tive for patients with high-risk stage 3 neuroblastoma.
Although the strategy with the HDCT/ASCR improved
the survival of patients with high-risk neuroblastoma, the
survival rate after a single HDCT/ASCR has been unsatis-
factory (7-11). Our recent report, which examined the effi-
cacy of tandem HDCT/ASCR to further improve the treat-
ment outcome of stage 4 neuroblastoma patients over 1 yr
of age, showed a better long-term EFS compared to studies
reporting on a single HDCT/ASCR strategy (12). The strat-
egy using a tandem HDCT/ASCR was based on the hypoth-
esis that further dose escalation might result in further im-
provements in the EFS of high-risk neuroblastoma patients.
In the present study, the tandem HDCT/ASCR was given
only if a CR was not achieved, even after the first HDCT/
ASCR, in the early period of the study. However, all patients
underwent tandem HDCT/ASCR during the late study peri-
od. As a result, while the tumor relapsed in two of eight pa-
tients in the single HDCT group, all 6 patients in the tan-
dem HDCT group remained relapse free. These findings sug-
gest that the tandem HDCT strategy may be better than the
single HDCT strategy for improved survival even in patients
with high-risk stage 3 neuroblastoma, although it was not
Fig. 3. Results of Kaplan-Meier analysis for the EFS of 14 patients who underwent HDCT/ASCR. The tumor relapsed in 2 out of 14 patients
and the remaining 12 patients remained event free with a median follow-up of 55 months (range 12-110) from the first HDCT/ASCR. (A) The
5-yr EFS rate after the first HDCT/ASCR for all 14 patients was 85.1±9.7%. (B) While tumor relapsed in 2 of 8 patients in single HDCT/ASCR
group, all 6 patients in tandem HDCT/ASCR group remained event free. 
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statistically significant in the present study. Further study
will be needed to evaluate whether tandem HDCT/ASCR is
better than single HDCT/ASCR in the treatment of high-risk
stage 3 neuroblastoma. In six patients who underwent tan-
dem HDCT/ASCR, the short-term toxicities were acceptable
during the second HDCT/ASCR. There was no life-threat-
ening toxicity during the second HDCT/ASCR. However,
long-term follow-up is needed to evaluate the long-term tox-
icities of the tandem HDCT/ASCR.
According to previous reports, patients treated for longer
periods, prior to HDCT/ASCR, had better long-term EFS
than those patients treated for shorter periods (9, 12). While
all the patients in the late study period received 9 cycles of
chemotherapy prior to the HDCT/ASCR, most of the pati-
ents in the early study period received 6 or 7 cycles of chemo-
therapy. The two patients in whom the tumor relapsed after
the HDCT/ASCR received 6 cycles of chemotherapy prior
to HDCT/ASCR, although they were in the CR or VGCR
prior to the HDCT/ASCR. Similarly, the tumor relapsed in
two of six patients who received 6 cycles of chemotherapy
prior to the HDCT, although the tumor status prior to the
first HDCT was CR in three patients and VGPR in three,
respectively. However, it is unclear whether the short dura-
tion of conventional chemotherapy was related to the high
relapse rate after HDCT/ASCR in the present study, because
all but one patient in the single HDCT/ASCR group received
6 or 7 cycles of chemotherapy prior to the first HDCT/ASCR
while all patients in the tandem HDCT/ASCR group received
9 cycles of chemotherapy. 
Immunotherapy with IL-2 along with CRA was provided
in an attempt to control the minimal residual disease after the
HDCT/ASCR. These two drugs were used simultaneously
because their major toxicities do not overlap and their differ-
ent mechanisms of action could synergistically eradicate any
minimal residual disease. While the efficacy of CRA has been
demonstrated (19-21), there have been few studies that have
evaluated the efficacy of IL-2 therapy (16). Therefore, it is
unclear if IL-2 therapy contributed to the improved survival
in the present study. However, there was no life-threatening
toxicity and an increase in the number of natural killer cells
was observed after IL-2 therapy (22). More study will be need-
ed to evaluate the efficacy of the IL-2 treatment after HDCT/
ASCR. 
The present study demonstrates that HDCT/ASCR, espe-
cially tandem HDCT/ASCR, may improve the prognosis of
patients with high-risk stage 3 neuroblastoma. However,
throughout this study, multiple modifications were made in
the treatment plan, which resulted in significant variability
over time between the patients. This variability may create
doubt as to whether tandem HDCT/ASCR actually resulted
in the improved outcomes. For example, a longer pre-HDCT
treatment in the tandem HDCT group compared with the
single HDCT group might have had an impact on the EFS
in the present study. Further study will be needed to evalu-
ate the efficacy of tandem HDCT/ASCR in the treatment of
high-risk stage 3 neuroblastoma. 
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